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The mammalian telencephalon plays critical roles in
cognition, motor function, and emotion. Though
many of the genes required for its development
have been identified, the distant-acting regulatory
sequences orchestrating their in vivo expression
are mostly unknown. Here, we describe a digital at-
las of in vivo enhancers active in subregions of the
developing telencephalon. We identified more than
4,600 candidate embryonic forebrain enhancers
and studied the in vivo activity of 329 of these
sequences in transgenic mouse embryos. We gener-
ated serial sets of histological brain sections for 145
reproducible forebrain enhancers, resulting in a
publicly accessible web-based data collection com-
prising more than 32,000 sections. We also used
epigenomic analysis of human and mouse cortex
tissue to directly compare the genome-wide en-
hancer architecture in these species. These data
provide a primary resource for investigating gene
regulatory mechanisms of telencephalon develop-
ment and enable studies of the role of distant-acting
enhancers in neurodevelopmental disorders.
INTRODUCTION
The telencephalon houses the cerebral cortex and basal ganglia,
structures that are pivotal for human brain functions (Wilson andRubenstein, 2000). Impaired telencephalic development and
function are associated with major neurological and neuropsy-
chiatric disorders, including mental deficiency, cerebral palsy,
epilepsy, schizophrenia, and autism (Lewis and Sweet, 2009;
Walsh et al., 2008a). Significant progress has been made toward
defining spatially resolved gene expression patterns in the devel-
oping and adult brains of mouse and human on a genomic scale
(Diez-Roux et al., 2011; Gong et al., 2003; Gray et al., 2004; Lein
et al., 2007; Portales-Casamar et al., 2010; Visel et al., 2004;
Zeng et al., 2012). In contrast, the distant-acting gene regulatory
sequences that are critical for orchestrating the spatial and
temporal expression of genes in the developing and adult brain
remain poorly defined despite evidence from large-scale human
genetic studies demonstrating the contribution of regulatory
sequences to a wide spectrum of human traits and disorders
(Durbin et al., 2010; Maurano et al., 2012) and anecdotal direct
evidence for a critical requirement for enhancers in brain devel-
opment (Kurokawa et al., 2004; Shim et al., 2012).
Unlike protein-coding genes, enhancers involved in specific
biological processes are difficult to identify because they reside
in the vast and poorly characterized noncoding portion of the
genome and can be located hundreds of thousands of base
pairs away from the promoters of the target genes that they
regulate (Lettice et al., 2003). The introduction of enhancer
prediction methods based on extreme evolutionary conserva-
tion (Nobrega et al., 2003; Pennacchio et al., 2006; Visel et al.,
2008) and chromatin immunoprecipitation sequencing (ChIP-
seq) (Visel et al., 2009a) increased the efficiency of identifying
enhancers. Importantly, ChIP-seq experiments that are per-
formed directly on tissues can provide accurate predictions of
the broad, general anatomical region in which an enhancer isCell 152, 895–908, February 14, 2013 ª2013 Elsevier Inc. 895
active (Visel et al., 2009a). Nevertheless, the spatial resolution of
these methods is limited, and detailed in vivo studies are
required to precisely define the activity patterns of enhancers
at high resolution.
To address the need for an improved understanding of the
cis-regulatory architecture and gene networks active during
telencephalic development, we combined sequence conserva-
tion- and ChIP-seq-based enhancer prediction with large-scale
histological activity analysis of human telencephalon enhancers
in transgenic mice. We demonstrate how the high-resolution
neuroanatomical annotation of enhancer activities can be used
to develop computational sequence classifiers for enhancers
active in different subregions of the telencephalon. We also
directly compare the genome-wide enhancer architecture active
in the mouse and human cortex using ChIP-seq from these
tissues, and we provide examples of downstream applications
for enhancers identified through this work.
RESULTS
Genome-wide Identification of Candidate Forebrain
Enhancers
To generate a genome-wide set of forebrain enhancer candidate
sequences, we collected forebrain tissue from embryonic day
11.5 (e11.5) mouse embryos and performed tissue-ChIP-seq
using an antibody for the enhancer-associated protein p300.
Results were analyzed alongside previously described data to
increase sampling depth (see Extended Experimental Proce-
dures, available online). Genome-wide enrichment analysis led
to the identification of 4,425 noncoding regions genome wide
that are distal from transcription start sites and significantly en-
riched in p300 binding in the e11.5 forebrain (Table S1A).
Because p300 was previously shown to be associated with
active tissue-specific enhancers (Blow et al., 2010; Visel et al.,
2009a), these sequences were predicted to be distant-acting
forebrain enhancers. As a complementary approach to identi-
fying candidate enhancers, we also used extreme sequence
conservation in conjunction with genomic location. Thus, we
scrutinized sequences under extreme evolutionary constraint
(Siepel et al., 2005; Visel et al., 2008) in the genomic vicinity of
79 genes with a known role in forebrain development or function
(Table S1B), and we identified 231 additional candidate fore-
brain enhancer sequences (Table S1C). Combined, these two
data sets comprised a total of 4,656 noncoding sequence
elements that we hypothesized to be enriched in forebrain
enhancers.
Transgenic Validation and Characterization
of Enhancers
To validate candidate telencephalon enhancer sequences and
define their in vivo activities in greater detail, we selected 329
elements predicted to be enhancers by conservation and/or
ChIP-seq for experimental testing (Table S1D). Nearly all of
these selected elements were located near genes with a known
function in the forebrain (Table S1B). In order to focus on the
most conserved core regulatory architecture of mammalian
telencephalon development, only ChIP-seq peaks that were de-
tectably conserved between the human and mouse genome896 Cell 152, 895–908, February 14, 2013 ª2013 Elsevier Inc.were tested. Regardless of the identification method, all tested
sequences showed evidence of significant evolutionary
constraint (phastCons scores ranging from 415 to 931, median
798; Table S1D). The selected candidate enhancer sequences
were amplified from human genomic DNA, cloned into an
enhancer reporter vector (Hsp68-LacZ), and used to generate
transgenic mice by pronuclear injection (see Experimental
Procedures). Transgenic embryos were stained for reporter
gene (LacZ) activity at e11.5, and reporter expression was anno-
tated using established reproducibility criteria (Pennacchio
et al., 2006). Only elements that drove expression in the fore-
brain in at least three embryos, each of them corresponding to
an independent transgenic integration event, were considered
as reproducible forebrain enhancers. In total, 105 of the 329
(32%) candidate sequences tested were reproducible forebrain
enhancers at e11.5, of which 36 showed reproducible expres-
sion exclusively in the forebrain (Table S1D). For comparison,
in previous transgenic assays of p300-binding sites in two
different nonneuronal tissues, limb buds and the heart, only 4
of the 155 (2.6%) tested sequences had reproducible forebrain
enhancer activity at e11.5 (Blow et al., 2010; Visel et al.,
2009a). Enhancer candidate sequences that overlapped p300
ChIP-seq peaks were more enriched in verifiable in vivo fore-
brain enhancers than extremely conserved sequences that
showed no evidence of p300 binding (58% compared to 23%,
Table S1D). Selected examples of reproducible forebrain
enhancers whose in vivo activity was confirmed in transgenic
mice are shown in Figure 1, and whole-mount images for all vali-
dated enhancers are accessible online through the Vista
Enhancer Browser (Visel et al., 2007).
High-Resolution Analysis of Telencephalon Enhancer
Activity Patterns
To define the precise spatial expression patterns of telence-
phalic enhancers active at e11.5, we performed high-resolution
analysis on a set of 145 enhancers (Table S1E). These sequences
were selected from the 105 forebrain enhancers discovered in
the present study and from complementary sets of forebrain
enhancers identified at whole-mount resolution in previous
enhancer screens (Pennacchio et al., 2006; Visel et al., 2008,
2009a). For each enhancer, a full set of contiguous coronal
paraffin sections (average: 220 sections) was obtained. Full-
resolution digital images of more than 32,000 sections are avail-
able through the Vista Enhancer Browser (Visel et al., 2007).
Selected sections of patterns driven by different enhancers in
subregions of the pallium (cortex), subpallium (basal ganglia),
and eminentia thalami (telencephalic-diencephalic connection)
are shown in Figures 2 and 3, illustrating the diversity of spatial
specificities observed.
In addition to the spatial activity patterns of all 145 enhancers
studied at e11.5, we also examined the temporal activities of
a subset of these enhancers at later prenatal stages of telen-
cephalon development (Figures 2S, 3F, and 3G). These temporal
comparisons showed that the spatial patterns of enhancer
activity were largely constant. In two cases, enhancers active
in subregions of the subpallium at e11.5 displayed characteristic
features of subpallial cell populations (interneurons) that tangen-
tially migrate to the pallium. At e13.5, these cells had just arrived
Figure 1. Expression of a Subset of Fore-
brain Enhancers Identified by Conservation
or p300 Binding at Whole-Mount Resolution
(A) A selection of 50 reproducible forebrain en-
hancers at e11.5 identified in this study. In each
case, only one of several (minimum of three)
embryos with the same pattern is shown. Addi-
tional embryos obtained with each enhancer
construct can be viewed at http://enhancer.lbl.
gov. Enhancer elements are sorted by broad
similarities of patterns as evident at whole-mount
resolution.
(B) Examples of genes implicated in forebrain
development that were screened for enhancers in
the present study and for which enhancers are
shown in (A).
A full list of all 329 constructs tested in this
study, including annotations of enhancer activity
patterns and information about neighboring genes,
is provided in Table S1D. See also Tables S1A–
S1C and S2.in the ventrolateral pallium (hs692 and hs799), and by e15.5 they
were in the dorsal pallium (hs799, arrowheads in Figures 3F and
3G). These results support the notion that enhancers regulate
both spatial and temporal aspects of telencephalic gene expres-
sion in patterns consistent with the biology of these regions and
cell types.
To facilitate analysis by computational methods, we devised
a standardized neuroanatomical annotation scheme for the
e11.5 stage of telencephalon development (Figures 2A, 3C,
and S1 and Table S1E). All telencephalon enhancer activity
patterns examined in this study were annotated using this stan-
dardized annotation scheme, in some cases complemented by
descriptions that further subdivide the standardized domains
or are restricted to subsets of cells (Table S1E). The standardized
annotations assigned to enhancers enable computational anal-
ysis of their activity patterns as well as a comparison to expres-
sion patterns of their presumptive target genes at this stage of
development.Cell 152, 895–908,Comparison of Enhancer Activities
to Gene Expression Patterns
To test whether the telencephalon
enhancers examined at high resolution
generally recapitulate the spatial expres-
sion patterns of their presumptive target
genes, we compared their LacZ reporter
activities to RNA in situ hybridization
data. For example, the Arx gene is ex-
pressed in both subpallial and pallial
regions, with increasing expression in
pallial regions from e11.5 to e13.5 (Fig-
ure 4A). We found that there are at
least four distant-acting telencephalic
enhancers in this extended locus, two of
which drive subpallial and two of which
drive pallial expression, indicating that
developmental Arx regulation is more
complex than initially suggested (Cola-sante et al., 2008). In addition, comparison of other genes with
well-established roles in telencephalon development (Lef1,
Wnt8b, Gsx2, Nr2f1) to nearby enhancers also revealed exam-
ples of spatially concordant enhancer activity and RNA expres-
sion (Figures 4B–4E). A recurring feature of these comparisons
is the restriction of individual enhancer activities to subregions
of the respective gene expression patterns, supporting the
modular structure of telencephalic enhancer architecture. For
instance, hs687 activity in the lateral ganglionic eminence
(LGE) matches Gsx2 RNA expression, whereas the latter is
also expressed in the medial ganglionic eminence (MGE);
hs1172 activity in the pallium matches Nr2f1 RNA expression,
whereas the gene is also expressed in the subpallium.
To assess whether these illustrative examples are representa-
tive of a general congruence between enhancer activity patterns
and the expression of nearby genes, we performed a quantitative
correlation analysis across the available data set (see Extended
Experimental Procedures for details). Overall, we found a highlyFebruary 14, 2013 ª2013 Elsevier Inc. 897
Figure 2. Subset of Forebrain Enhancers with Activity in Different Dorsoventral Subregions of the Developing Mouse Pallium
(A) Overview of annotated structures in the approximate coronal sectioning plane shown in (B–R).
(legend continued on next page)
898 Cell 152, 895–908, February 14, 2013 ª2013 Elsevier Inc.
significant correlation between the activity patterns of enhancers
and telencephalic expression patterns of nearby annotated
genes (p = 0.0003, Mann-Whitney test, Figure 4F). In addition
to the high-resolution comparisons of enhancer and gene
activity patterns, we also examined whether the genome-wide
set of 4,425 forebrain enhancer candidate sequences identified
by ChIP-seq from embryonic mouse forebrain tissue is associ-
ated with genes with known functions in the telencephalon.
Unbiased genome-wide assessment (McLean et al., 2010)
showed highly significant enrichment in genes that cause fore-
brain-related phenotypes when deleted in mouse models (Table
S2). These observations support on a genomic scale that the
large set of forebrain candidate enhancers predicted by ChIP-
seq in this study is enriched near genes that are involved in telen-
cephalon development.
Sequence Analysis of Subregion-Specific Enhancers
A large set of telencephalon enhancers, analyzed at high spatial
resolution and annotated to a standardized scheme, offers the
possibility to examine sequence features that are associated
with in vivo activity in different telencephalic subregions. To
explore this regulatory code, we trained a random forest (RF)
classifier (Breiman, 2001; Bureau et al., 2005; Cummings and
Segal, 2004; Lunetta et al., 2004) to discriminate between
random genomic sequences and enhancers active in (1) pallium
only, (2) pallium and subpallium (compound pattern), or (3) sub-
palliumonly (see Figures 5, Figures S2–S5, and Extended Exper-
imental Procedures). Classification is based on the presence or
absence of combinations of sequence motifs matching known
transcription factor binding sites (Bryne et al., 2008; Matys
et al., 2006). The five most relevant motifs distinguishing the
three classes of enhancers and their respective importance are
shown in Figure 5B (for additional motifs, see Figure S2 and
Table S1G). We did not observe any single motif that was suffi-
cient to accurately discriminate between the different classes
of enhancers, suggesting that only the combinatorial binding of
multiple transcription factors determines the observed spatial
regulatory activity. Themajority of themost discriminatory motifs
(at least 60% of the top 15 motifs characterizing enhancers
active in each of the telencephalic subregions considered) corre-
spond to predicted binding sites for homeodomain-containing
transcription factors, consistent with the known critical role of
these proteins in telencephalon development (He´bert and Fish-
ell, 2008). Figure S3 summarizes the enrichment of the 15 most
relevantmotifs for enhancer activity in the three different telence-
phalic subregions considered. Despite possible ambiguities
associated with computational transcription factor binding site
predictions, the RF classifier accurately predicts 80% of the
sequences (see Extended Experimental Procedures and Table
S3). Sequence motifs with high quantitative importance for(B–R) Selected enhancers that reproducibly label subregions of the developing
dorsal, lateral, and ventral pallium. Detailed annotations of all patterns, as well as
Table S1E. Full serial sets of sections for each enhancer can be viewed at http:/
(S) Comparison of enhancer activities between e11.5 and e13.5. Red arrowhe
arrowheads indicate immature neurons in the cortical plate.
Cx, cortex; CxP, cortical plate; DP, dorsal pallium; LGE, lateral ganglionic eminen
also Figure S1 and Tables S1A–S1D.discriminating between different classes of telencephalon
enhancers are overall more conserved in evolution compared
to nonimportant motifs, supporting their functional relevance
(Figure S4).
These computational predictions of relevant sequence motifs
provide a starting point for experimental studies aimed at under-
standing the transcription factor binding site content of telen-
cephalon enhancers in greater detail. To illustrate the value of
a large set of enhancers with known sequences and activity
patterns for studying genetic dependencies in telencephalon
development, we tested a subset of subpallial enhancers for
their direct regulation by two major subpallial transcription
factors, Dlx2 and Ascl1 (see Extended Experimental Proce-
dures). In a cell-based luciferase assay, we observed that Dlx2
and/or Ascl1 significantly increased reporter expression when
cotransfected with 13 of 20 tested enhancers (Figure 5C). Of
note, these enhancers are located near several genes with
known roles in subpallium development, and the results are
consistent with previous studies demonstrating that Dlx2 regu-
lates the expression of Arx,Meis2, and Sp8 and that Ascl1 regu-
lates the expression of Sox4 (Castro et al., 2011; Colasante et al.,
2008; Long et al., 2009). Considering the expected complexity of
the spectrum of transcription factors binding to different subsets
of telencephalon enhancers (Figure 5B and Table S1G), comple-
mentary scalable methods will be required to experimentally
validate all binding sites within each of the enhancers identified.
Our cell-based studies of a small subset of these sequences
highlight, however, that the combined knowledge of the genomic
location, the spatial activity, and the upstream transcription
factors of discrete, distant-acting regulatory sequences gener-
ates hypotheses that are directly testable in genetic in vivo
systems.
Human Brain ChIP-Seq
Our large-scale transgenic testing and high-resolution analysis
of telencephalon enhancers focused on sequences that are
highly conserved in evolution, with the goal being to characterize
the most conserved core regulatory architecture of mammalian
telencephalon development. However, epigenomic methods
also enable the systematic discovery of poorly conserved and
lineage-specific enhancers (Schmidt et al., 2010). To explore
possible differences between human and mouse telencephalon
enhancers in greater detail, we determined the genome-wide
occupancy of the enhancer-associated proteins p300/CBP in
human fetal (gestational week 20) cortex (Figures 6A and 6B).
ChIP-seq analysis identified 2,275 peaks (candidate enhancers)
genome wide that were located at least 2.5 kb from the nearest
transcript start site. Comparison with transcriptome data from
human fetal cortex tissue revealed a 2.7-fold enrichment in
candidate enhancers within 2.5–20 kb of the transcript start sitespallium. Enhancers are arranged by their spatial specificities in the medial,
additional enhancers that drive expression in these subregions, are provided in
/enhancer.lbl.gov, using the enhancer IDs indicated in the figure panels.
ads indicate activity in neuronal precursor/differentiation zones, and orange
ce; LP, lateral pallium; MP, medial pallium; VP, ventral pallium; Se, septum. See
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Figure 3. Subset of Forebrain Enhancers with Activity in Different Subregions of the Mouse Subpallium and Eminentia Thalami
(A–E) Selected enhancers that target LacZ expression (A) predominantly or exclusively to subregions of the LGE, (B) predominantly to the MGE, (D) both to the
LGE and to MGE, and (E) to the EMT. (C) Schematic overview of structures in the approximate sectioning plane shown in (A), (B), (D), and (E). Depending on the
rostrocaudal extent of staining, for some enhancers, more rostral or caudal planes were chosen to illustrate salient features of the respective patterns.
(F and G) Comparison of enhancer activities between e11.5, e13.5, and e15.5. White arrowheads indicate cell populations whose location is consistent with
migration from the MGE, through the LGE, and to the cortex.
CP, choroid plexus; Cx, cortex; CxP, cortical plate; EMT, eminentia thalami; DP, dorsal pallium; LGE, lateral ganglionic eminence; LP, lateral pallium; MGE,
medial ganglionic eminence; MP, medial pallium; MZ, marginal zone; POA, preoptic area; Str, striatum; VP, ventral pallium; Th, thalamus. See also Figure S1 and
Tables S1A–S1D.
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Figure 4. Correlation of Spatial Enhancer
Activity Patterns with RNA Expression
Patterns of Nearby Genes
(A–E) Examples of individual enhancers recapitu-
lating aspects of the gene expression patterns.
(A) The Arx gene is expressed in subpallial (blue
arrows) and pallial (black arrows) regions. Pallial
expression increases from e11.5 to e13.5 (insets).
At least four enhancers in the extended locus drive
subpallial (hs119, hs121) or pallial expression
(hs122, hs123) at e11.5.
(B–E) Additional examples of overlap in enhancer
activity with expression of nearby genes in rostral
(top) and more caudal (bottom) areas of the
telencephalon at e11.5. In all four cases, there was
spatial overlap in activity (green arrowheads), as
well as gene expression in additional regions that
did not show enhancer activity (red arrowheads).
(F) To assess overall correlations, the annotated
activity patterns of telencephalic enhancers were
compared to RNA expression patterns of nearby
genes. Compared to randomly assigned pairs of
genes and enhancers, there is a highly significant
enrichment of cases inwhich concordant enhancer
activity and gene expression are observed in one
or multiple telencephalic subregions (p = 0.0003,
Mann-Whitney test; error bars represent SEM).
Arx RNA in situ hybridization images in (A): Allen
Developing Mouse Brain Atlas (http://developing
mouse.brain-map.org), reproduced with permis-
sion from Allen Institute for Brain Science. See
also Tables S1A–S1D.of genes highly expressed in fetal human cortex (p < 1 x 1014,
binomial distribution), with significant enrichment up to 220 kb
away from promoters (p < 0.001, binomial distribution, Fig-
ure 6C). In contrast, no enrichment of p300/CBP binding sites
was observed near genes highly expressed in other tissues.
Similar to candidate enhancers predicted from mouse e11.5
forebrain, unsupervised statistical enrichment analysis of func-
tional gene annotations (McLean et al., 2010) showed significant
association with genes implicated in nervous-system-related
phenotypes (Table S2). Although many extremely conserved
noncoding sequences in the human genome are enhancersCell 152, 895–908,active in the developing nervous system
(Pennacchio et al., 2006), we observed
that one-third (36.5%) of ChIP-seq-pre-
dicted human brain candidate enhancers
are under weak (phastCons < 350) or no
detectable evolutionary constraint, sug-
gesting that subsets of human brain
enhancers may not be functionally
conserved in mice.
At gestational week 20, the human
cortex is considerably further developed
than the mouse pallium at e11.5 and
instead corresponds broadly to early
postnatal stages in mouse (Clancy et al.,
2007). To enable a direct experimental
comparison between the two species,we performed p300/CBP ChIP-seq on mouse postnatal (P0)
cortex tissue. Using identical methods to those used for
human tissue, we identified 1,132 candidate enhancers (distal
ChIP-seq peaks). The majority (58%) of human-derived peaks
showed significant or suggestive (subsignificant) enrichment in
ChIP-seq reads at the orthologous site in the mouse genome
(Figure 6D). The remaining 42% either showed no enrichment
in the orthologous mouse region or were not alignable to the
mouse genome. Though the lower sequencing coverage in the
mouse data set may lead to an underestimation of mouse-
compared to human-specific peaks (compare Figures 6DFebruary 14, 2013 ª2013 Elsevier Inc. 901
A B
C
Figure 5. Relating Sequence Motif Content to High-Resolution Activity Annotations
(A) Red squares indicate enhancers (rows) active in different telencephalic subregions (columns). Unsupervised clustering (Jaccard’s coefficient, average linkage)
of telencephalic subregions by similarity of enhancer activity profiles (top dendrogram) largely follows known developmental, functional, and topological relations
of telencephalic subregions. Clustering (Euclidean distance, Ward’s method) of enhancers by similarity of observed activity in telencephalic subregions suggests
(legend continued on next page)
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Figure 6. Genome-wide Experimental Comparison of Enhancers Active during Human and Mouse Cortex Development
(A) ChIP-seq analysis was performed on human gestational week 20 and mouse postnatal day 0 cortex tissue using an antibody directed against the enhancer-
associated p300/CBP proteins.
(B) Two representative peaks (candidate enhancers) identified from the human fetal data set.
(C) Predicted human fetal cortex enhancers are significantly enriched in the larger vicinity (up to 220 kb away) of genes highly expressed in the human fetal cortex.
Error bars represent the 90% confidence interval on the basis of 1,000 iterations of randomized distribution (see Extended Experimental Procedures).
(D) The majority of candidate enhancers identified from human fetal cortex show evidence of p300/CBP binding at orthologous sites in the mouse genome (top
two sectors of heat map). However, a substantial proportion of human peaks either shows no evidence of p300/CBP binding at orthologous sites in the mouse
genome (third sector) or falls into regions of the human genome that have no known orthologous sequence in the mouse (fourth sector).
(E) A substantially larger proportion of mouse P0 cortex candidate enhancers was found to be bound by p300/CBP at orthologous sites in the human genome.
(F–K) Transgenic activity analysis of two candidate enhancers (B) in transgenic mice at postnatal day 1. Each pattern was reproducible in a minimum of three F0
animals; three sectioning planes from one representative brain per enhancer are shown. Red arrows indicate expression in the cortex.and 6E), the presence of 307 peaks in nonalignable regions of the
human genome (Figure 6D) supports that a nonnegligible
proportion of human brain enhancers emerged in evolution after
the divergence of primates and rodents from their last common
ancestor.functional subgroups (right dendrogram). Shades of gray indicate the proportion o
pallium and subpallium enhancers) or to the compound pallium/subpallium class
(B) RF classifier distinguishes enhancers that are active in pallium only (top), in both
sequence motifs characterizing each class of enhancers and their relative contr
Receiver-operating characteristic (ROC) curves of predictive performances. The a
predictions while maintaining sensitivity in true predictions. For example, the ‘‘pa
cluster at a false positive rate of 10%.
(C) Luciferase cotransfection assays of 20 subpallial enhancers with either the tr
See also Figures S2–S5 and Tables S1E–G, S2, and S3.Similar to the large collection of telencephalon enhancers
identified and characterized at e11.5, ChIP-seq peaks derived
from human fetal cortex are expected to include enhancers
with a variety of in vivo activity patterns. To illustrate this, we
examined the in vivo activities of candidate enhancers fromf decision trees assigning each enhancer to the pallium or subpallium class (for
(for compound enhancers).
pallium and subpallium (center), and in subpallium only (bottom). (Left) Top five
ibution to the classification. Additional motifs are shown in Figure S2. (Right)
rea under the curve (AUC) measures the ability of the classifier to limit incorrect
llium and subpallium’’ classifier correctly identifies 70% of enhancers in this
anscription factors Dlx2 or Ascl1 in P19 cells. Error bars represent SD.
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human fetal cortex in postnatal transgenic mice. Two examples
of such enhancers driving reproducible expression in a
minimum of three independent transgenic animals are shown
in Figures 6F–6K. Consistent with the ChIP-seq prediction,
both enhancers were active in the cortex (red arrows) as well
as in additional but distinct and reproducible regions of the
telencephalon.
To illustrate the value of the genome-wide sets of human and
mouse candidate enhancers for the interpretation of human
genetic data sets, we compared the genomic position of these
sequences with different catalogs of regions in the human
genome implicated in neurodevelopmental, neurological, or
neuropsychiatric diseases. We intersected the genome-wide
sets of candidate enhancers identified in the three different
ChIP-seq experiments with (1) lead single-nucleotide polymor-
phisms (SNPs) from genome-wide association studies of
relevant traits (Hindorff et al., 2009), (2) catalogs of syndromic
microdeletions and microduplications (Firth et al., 2009), and
(3) a set of autism-associated rare copy-number variants
(Marshall et al., 2008; Szatmari et al., 2007). Fourteen lead
SNPs from genome-wide association studies, including SNPs
associated with attention deficit hyperactivity disorder, bipolar
disease, and schizophrenia, were found to be located within pre-
dicted forebrain enhancers. Moreover, 381 enhancers mapped
within recurrent microdeletions or microduplications associated
with neurological phenotypes, and 421 enhancers overlapped
copy-number variants present in autism cases, but not healthy
controls. Though further experimental studies will be required
to examine possible causal roles of variants affecting enhancer
sequences, the genome-wide sets of candidate enhancers iden-
tified from human and mouse brain tissue through this study
provide a starting point to explore the role of telencephalon
enhancers in human diseases.
Telencephalon Enhancers as Molecular Reagents
The enhancers described in our high-resolution atlas can be
used as molecular reagents to drive in vivo expression of
reporter or effector genes to specific telencephalic subregions
of interest, owing to the reproducibility of their activity patterns
(Figure 7A). To illustrate some of the resulting applications, we
coupled enhancer hs1006, associated with the WNT8B gene,
to a minimal Hsp68 promoter, followed by a tamoxifen-inducible
Cre recombinase (CreERT2), an internal ribosomal entry site, and
a green fluorescent protein (GFP) reporter (Figure 7B). In stable
transgenic mouse lines generated with this construct, termed
CT2IG-hs1006, GFP expression at e11.5 was indistinguishable
from LacZ reporter expression (Figures 7A and 7B). GFP expres-
sion in these stable lines facilitates a temporally resolved
mapping of enhancer activity. A comparison of GFP activity at
e12.5, e15.5, and e17.5 with Wnt8b RNA expression reveals
that enhancer activity spatially coincides with Wnt8b gene ex-
pression, indicating that this enhancer controls region-specific
expression of the gene over an extended period of prenatal
telencephalon development.
Because expression of the compound effector/reporter tran-
script in CT2IG-hs1006 mice faithfully resembledWnt8b expres-
sion across multiple stages of development, the chemically
inducible CreERT2 recombinase can be used for spatially and904 Cell 152, 895–908, February 14, 2013 ª2013 Elsevier Inc.temporally highly restricted genomic recombineering applica-
tions such as neuronal fate mapping studies. To demonstrate
this, we crossed CT2IG-hs1006 mice with Rosa26-LacZ mice
(Figure 7B) (Indra et al., 1999). Tamoxifen induction of CreERT2
in pregnant compound CT2IG-hs1006:Rosa26-LacZ mice at
e10.5 leads to recombination only in the small proportion of
pallial cells in which the enhancer is active at this time point.
LacZ staining at later stages revealed the spatial fate of cells in
which the enhancer was active at e10.5. For example, hs1006-
driven e10.5/ e12.5 fate mapping marked pallial cell popula-
tions with a distribution that is clearly distinct from hs1006
activity at this time point (compare e12.5 patterns in Figures
7C and 7D). These data highlight the utility of these enhancers
to precisely drive gene expression in the developing brain and
their value as a rich resource for a diversity of uses.
DISCUSSION
This work provides a comprehensive resource for basic studies
of telencephalon enhancers. Our targeted screen identified the
genomic location of thousands of candidate enhancers puta-
tively active in the embryonic forebrain. The mapping and anno-
tation of the activity patterns of nearly 150 human telencephalon
enhancers at histological resolution in transgenic mice provide
insight into the regulatory architecture of individual genes that
are required for forebrain development and will facilitate studies
of molecular genetic pathways by identifying the genomic
regions to which upstream transcription factors bind.
Our analysis revealed several cases of enhancers that drive
similar patterns and are associatedwith the same gene (e.g., Fig-
ure 4A) in a manner reminiscent of the ‘‘shadow enhancers’’
observed in invertebrate models (Frankel et al., 2010; Hong
et al., 2008). The data provided through this work will support
the identification of minor spatial activity differences between
such enhancers, as well as the functional exploration of their
apparent redundancies. It is also remarkable that a large propor-
tion of enhancers examined in this study drove patterns that
were at least partially different from all other enhancers exam-
ined, highlighting the complexity of the developing forebrain,
as well as the regulatory sequence code orchestrating its
development.
The motif-based classifiers derived from enhancers active in
different subregions of the telencephalon demonstrate the value
of systematically annotated enhancer activity data sets for
computational studies aimed at deciphering the correlation
between the transcription factor binding sites present in an
enhancer and its precise spatial activity pattern. Beyond such
functional genomic studies, the enhancers identified and char-
acterized in this work provide a comprehensive set of molecular
reagents that can be used to target gene expression to defined
subregions of the developing brain or to defined cell states
when differentiating stem cells in vitro. This will enable tissue-
specific homologous recombination and deletion strategies or
expression of reporter and selectable genes, as illustrated in
Figure 7.
Finally, results from this study are expected to enable and
facilitate the functional genomic exploration of the role of
enhancers in human brain disorders. There is accumulating
AB
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Figure 7. Using Telencephalon Enhancers as Tissue-Specific Reagents
(A) Approach used for the generation of the large-scale high-resolution atlas at e11.5.
(B) Enhancers can be used as drivers of other reporter and effector genes, such as GFP or tamoxifen-inducible Cre recombinase. GFP reporter expression at
e11.5 recapitulates the annotated LacZ expression pattern (orange arrowheads). Schematic components of constructs in (A) and (B) are not shown to scale.
(C) Stable transgenic lines facilitate temporal profiling of enhancer activity and comparisons with corresponding gene expression patterns.
(D) Tamoxifen induction at e10.5, followed by LacZ staining at a later time point (shown: e12.5) can be used for developmental fate mapping of neuronal cell
populations.evidence that noncoding sequence variants, as well as copy-
number variation in coding and noncoding portions of the
genome, have important impacts on a wide spectrum of disor-
ders, including bipolar disorder, schizophrenia, autism, intellec-
tual disability, and epilepsy (Cooper et al., 2011; Durbin et al.,
2010; International Schizophrenia Consortium, 2008; Malhotraet al., 2011; Sebat et al., 2007; Vacic et al., 2011; Visel et al.,
2009b; Walsh et al., 2008b). However, the functional interpreta-
tion of noncoding sequence or copy-number variants remains
a major challenge, and few potentially causative connections
linking neurological traits to molecular variation in enhancers
have been identified (e.g. Poitras et al., 2010). Thus, theCell 152, 895–908, February 14, 2013 ª2013 Elsevier Inc. 905
systematic mapping and high-resolution analysis of telenceph-
alon enhancers through this work are expected to provide func-
tional genomic insights to guide studies that will mechanistically
relate individual noncoding sequence and copy-number variants
to brain disorders.
EXPERIMENTAL PROCEDURES
Chromatin Immunoprecipitation Sequencing
ChIP-seq on forebrain tissue isolated from e11.5 CD-1 strain mouse embryos,
using an antibody directed against p300, was performed according to previ-
ously described procedures (Visel et al., 2009a). For human tissue ChIP-seq
and the matched mouse postnatal cortex data set, an anti-acCBP/p300
pan-specific antibody was used (May et al., 2011).
All procedures of this study involving human tissue samples or animals were
reviewed and approved by the respective institutional Human and Animal
Regulatory Committees at Lawrence Berkeley National Laboratory and the
University of California at San Francisco.
Transgenic Mouse Assays
Enhancer candidate regions were analyzed in transgenic mouse embryos as
previously described (Kothary et al., 1988; Pennacchio et al., 2006). Paraffin
sections were prepared according to standard protocols. Serial sets of
sections were digitally photographed and uploaded to the Vista Enhancer
Browser (http://enhancer.lbl.gov).
GFP Reporter Assays and Cell Fate Mapping
A previously described Cre-ERT2 construct (Feil et al., 1997) was modified
to allow Cre recombinase expression to be driven by the hs1006 enhancer
(Figure 7B). For fate mapping, CT2IG-hs1006 mice were crossed with
Rosa26-LacZ reporter mice (Soriano, 1999).
Luciferase Assays
Dlx2 and Ascl1 were selected for luciferase reporter assays due to their
well-established roles in subpallial development and because they are repre-
sentatives of two major groups of transcription factors found among the top
motifs of the subpallium classifier (see Extended Experimental Procedures).
P19 cells were grown by previously described methods (Farah et al., 2000).
Data and Reagent Availability
Images of whole-mount-stained embryos and full sets of e11.5 coronal brain
sections are available through the Vista Enhancer Browser (http://enhancer.
lbl.gov). All enhancer reporter vectors described in this study are freely avail-
able from the authors. In addition, archived surplus transgenic embryos for
many constructs can be made available upon request for complementary
studies. The genome-wide set of ChIP-seq peaks derived from mouse e11.5
forebrain is provided in Table S1A. Raw data and additional ChIP-seq data
sets from postnatal mouse and fetal human cortex are available from GEO
under accession number GSE42881.
ACCESSION NUMBERS
The GEO accession number for the ChIP-seq data reported in this paper is
GSE42881.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and three tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2012.12.041.
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